|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | 1.91% | Shs Outstand | 17.51M | Perf Week | -12.84% |
Market Cap | 72.49M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | - | Perf Month | 1.72% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 14.49% | Short Float | - | Perf Quarter | -2.59% |
Sales | 1.00M | P/S | 72.49 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.39 | Perf Half Y | 2.73% |
Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | -27.50% |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 2.20 - 14.40 | Perf YTD | 8.66% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -71.25% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 88.18% | ATR | 0.50 |
Employees | - | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 38.79 | Volatility | 9.65% 10.78% |
Optionable | Yes | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.47 | Prev Close | 4.10 |
Shortable | Yes | LT Debt/Eq | - | Earnings | Mar 02 BMO | Payout | - | Avg Volume | 902.55K | Price | 4.14 |
Recom | - | SMA20 | -22.96% | SMA50 | -11.07% | SMA200 | -21.40% | Volume | 431,957 | Change | 0.98% |
![]() | ||||||||||
![]() | ||||||||||
|
||||||||||
![]() | ||||||||||
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel. | ||||||||||
![]() | ||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite